Scientists developed daraxonrasib, a drug that targets the KRAS mutation driving most pancreatic cancers and nearly doubled patient survival in clinical trials. KRAS had long been considered difficult to drug because of its smooth protein surface resisting conventional inhibitors.
Pancreatic cancer carries among the lowest survival rates of major malignancies, with limited effective treatments available after diagnosis. Targeting KRAS directly addresses a molecular driver present in a large share of pancreatic tumors.
Trial results showing nearly doubled survival represent a meaningful advance in an oncology field that has seen few breakthrough therapies. Regulatory review and broader patient access will depend on continued safety and efficacy data.
The development adds to a wave of KRAS-targeted medicines emerging after decades of research frustration. Oncologists are watching whether combination regimens can extend benefits further among metastatic pancreatic cancer patients.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/news/health_medicine/